cyrilzakka/clinical-trials huggingface dataset:
To Investigate the Effects of Robotic-assisted Gait Training in Stroke Patients

The primary aim of the study was to investigate the effects of robot-assisted gait training and virtual reality on knee joint position sense in patients with chronic stroke. The secondary objective is to examine the effectiveness of these applications on functional gait and balance.

Despite widespread prevention programs worldwide and advances in acute and subacute management and treatment protocols, stroke remains one of the most common causes of adult disability, representing a serious global health problem. Sensory motor dysfunction, proprioception deficits and hypertonus may develop in stroke patients depending on the location and severity of the brain damaged areas. Virtual reality application, which has been widely used in recent years, is a three-dimensional, computer-generated technology that gives the patient a sense of reality and allows the patient to interact with it. Virtual reality application can be used as a suitable method for proprioceptive rehabilitation due to its ability to manipulate visual feedback of virtual objects. In recent years, another technological method that has been used in the field of neurorehabilitation is robotic rehabilitation. Robot-assisted gait training, which requires repetitive tasks, can enhance neuroplasticity and motor learning, which focuses on the rearrangement of brain tissue. Both technology-based rehabilitation approaches have been shown to be particularly effective in improving the sense of position in the upper extremity. However, studies investigating the effects of these two applications on lower extremity position sensation seem to be insufficient. We think that both methods will be effective in improving the sense of position.

Eligibility Criteria:
Inclusion Criteria:

* Having been diagnosed with stroke by specialist physician,
* 6 months after stroke diagnosis,
* Hemiplegia or hemiparesis due to stroke for the first time,
* Being over 18,
* Being able to walk with auxiliary device or independently,
* Mini Mental test score\> 24,
* Functional Ambulation Classification FAC ≥ 2,
* Agree to participate in the study.

Exclusion Criteria:

* Acute internal discomfort,
* Botulinum toxin administration during 6 months before treatment or during treatment,
* Presence of a history of previous stroke,
* Having influence on both sides,
* Neglect syndrome,
* Presence of severe spasticity (Modified Ashwort Scale\> 2),
* Patients weighing more than 100 kg,
* Patients with femoral lengths greater than 50cm
Linked Color Imaging vs. White Light for Colorectal Dysplasia in Ulcerative Colitis

The purpose of the study is to determine whether a new colonoscopic viewing technique called Linked color imaging(LCI) helps endoscopists detect more dysplasia lesions in ulcerative colitis patients than conventional colonoscopy using white light alone.

Patients with longstanding IBD have increased risk of colorectal cancer (CRC) compared to the general population. The association between duration of the disease and development of CRC is the rationale for endoscopic surveillance. Colonoscopic surveillance of ulcerative colitis patients has been shown to reduce the risk of colorectal cancer and allow detection at an earlier stage, but even with meticulous examination, some precancerous lesions or cancers are missed. The newly developed LCI system (FUJIFILM Co.) creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of BLI technology. LCI makes red areas appear redder and white areas appear whiter. Thus, it is easier to recognize a slight difference in color of the mucosa. This is a study to determine if using Linked color imaging (LCI) of the colon, rather than the usual white light on the colon, will improve the detection of more dysplasia lesions in ulcerative colitis.

Eligibility Criteria:
Inclusion Criteria:patients with ulcerative colitis who meet surveillance criteria Exclusion Criteria:pregnant patients,unable or unwilling to give informed consent,patients with severe active colitis who would be unsafe to endoscope
Lidocaine-Prilocaine Cream (EMLA) Topical Application Versus Wound Infiltration With Lidocaine After Cesarean Section

A Comparison Between Lidocaine-Prilocaine Cream (EMLA) Application And wound Infiltration with Lidocaine For Post Caesarean Section Pain Relief : A Randomized Controlled Trial.

The purpose of this study is to compare the effectiveness of topically applied lidocaine-prilocaine (EMLA) cream with local anesthetic (lidocaine) infiltration on post-cesarean section pain.

Research Question:

Is lidocaine-prilocaine (EMLA) cream application effective as compared to local anesthetic (lidocaine) infiltration on post-caesarean section pain?

Research Hypothesis:

Lidocaine-prilocaine (EMLA) cream application is effective in post_caesarean section pain as compared to local anesthetic (lidocaine) infiltration.

Clinical Application :

Topical Lidocaine-prilocaine (EMLA) cream could be applied frequent times postoperatively, unlike infiltration with local anesthetic.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 and 40 years.
2. Patient American Society of Anesthesiologists physical status І or П.
3. Gestational age of pregnancy of 37w or more.
4. Patient have no previous section or have 1or 2 previous sections.
5. Patient having no medical disorders.
6. Patient with no obstetrical complications.

Exclusion Criteria:

1. age below18 or above 40.
2. Women American Society of Anesthesiologists physical status ш or more.
3. Women having more than 2 previous cesarean section.
4. Women receive cardio vascular drugs or having history of cardio vascular disease.
5. Women with Medical disorders with pregnancy as diabetes milletus.
6. Women having obstetrical complications as antepartum hemorrhage, pre-eclampsia or eclampsia.
7. Women having metabolic, hormonal, respiratory, renal and hepatic disease.
8. Women with any severe allergic condition or severe asthma.
9. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.
The Effect of Attention Distractor on the Quality of Chest Compression

The investigators plan to investigate the effect of attention distractor on the quality of chest compression during cardiopulmonary resuscitation. For this, a simulated study with Manikin is performed and the paced auditory serial addition test (PASAT) is used for distracting performer's attention.


Eligibility Criteria:
Inclusion Criteria:

* healthy volunteers who completed basic life support course among medical personnel (doctors, nurses, paramedics) working in a university hospital

Exclusion Criteria:

* pregnancy
Comparison of Bowel Cleansing Regimens Prior to Colonoscopy

The purpose of this study is to to compare two bowel preparation regimens of patients who will undergo colonoscopy, in terms of quality of bowel preparation and in terms of patient satisfaction.


Eligibility Criteria:
Inclusion Criteria:

• Subjects who are candidate to undergo colonoscopy: Diagnosis Screening Follow-up after previous polypectomy

* Informed consent
* Age \> 18 years

Exclusion Criteria:

* Previous colonic resection
* Severe inflammatory bowel disease (IBD)
Effectiveness of a Real Time Data Safety Study Tool

Study RTD-01 is a non-interventional, pilot study designed to determine if a specific coded SMS text message study tool is effective in collecting daily real time safety data in subjects participating in clinical trials.

This study is to determine if a daily SMS text message study tool will improve adverse event and concomitant medication reporting. Patient reported adverse events and changes in concomitant medications are essential in clinical trials to determine drug-related symptoms and side effects. This study will help identify the benefits and challenges of real time daily reported outcome measures that can later be implemented in future clinical trials to enhance trial outcomes. In addition, data collected from this study will support a more sophisticated safety study tool for future study participants.

Eligibility Criteria:
Inclusion Criteria:

* 18-85 age inclusive
* Male or Female
* Currently enrolled in an ongoing clinical trial
* Capable of providing informed consent and complying with daily study procedures
* Must be able to receive and respond to text messages through phone provider

Exclusion Criteria:

* Subjects not currently involved in a clinical trial
* Subjects who cannot receive text messages
* Unable to comply to the study protocol and study visits
A Study on the Use of a Brace Following Low Back Surgery

This study evaluated the hypothesis that bracing following lumbar spinal fusion surgery improves functional outcome following surgery


Eligibility Criteria:
Inclusion Criteria:

* Age 18-80
* Undergoing posterior lumbar fusion surgery for degenerative conditions

Exclusion Criteria:

* Unable to complete questionnaires due to language or cognitive barrier
* Declined study participation
Effectiveness of Rubber Dam Isolation Versus Cotton Roll Isolation on Bonded Fissure Sealant Retention

The purpose of this study is to evaluate and compare the clinical retention of bonded fissure sealants placed under rubber dam isolation and cotton roll isolation.


Eligibility Criteria:
Inclusion Criteria:

* Teeth having a clinical indication of sealing with bonded resin pit and fissure sealants
* Patients with four fully-erupted permanent molars, with unstained, caries-free and unsealed pit and fissures

Exclusion Criteria:

* Patients having incipient carious lesions, fewer erupted molars or teeth without pits on buccal/palatal surfaces.
* Patients with systemic diseases.
The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects

This study is a single-center, randomized, open, double-cycle and double-cross and self-reflection phase Ic clinical trial, to evaluate effect and safety of high fat diet on pharmacokinetics of SPH3127 tablets.

Two panels, each consisting of ten participants (The number of single-sex subjects is not less than 1/3 of the total number) will be randomized to A or B groups.

Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.

Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.

Eligibility Criteria:
Inclusion Criteria:

* The body mass index is 19 \~ 26kg/m2 (including the critical value), which allows the minimum weight of male to be 50kg (including the critical value) and 45kg (the critical value) for women.
* Before the study, participants have kown about the significance, potential benefits, inconveniences and potential risks of the study and can follow the research's procedure and already sign the informed consent

Exclusion Criteria:

* Participant who pregnancy, lactating women, and plan to get pregnant within six months after the clinical trial
* Participant who has significant abnormal physical examination, laboratory examination results (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal)
* Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality
* Participant who has drug allergy history, allergy constitution
* Participant who took oral contraceptives within 6 weeks
* Participant who used any drug (including Chinese herbal medicine) within 1 week
* Participant who donated blood within 2 months
* Participant who participated clinical trials of any drug in the past 3 months (as subjects)
* Participant who has any positive result of virus serology check : human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - Immunoglobulin G（IgG)antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP)
* Participant who are smoking, drinking, drinking coffee, strong tea and drug abusers
* Participant who the researchers believe that there are volunteers who are not suitable for the study
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.


Eligibility Criteria:
Inclusion Criteria:

* healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent
* who are available for all visits and telephone calls scheduled for the study
* who are up-to-date with age-appropriate routine childhood vaccinations

Exclusion Criteria:

* whose parent or legal guardian is unwilling or unable to give written informed consent
* who had a previous or suspected disease caused by N. meningitidis;
* who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
* who have received any investigational agents or vaccines within 90 days prior to enrollment
* who have any serious acute, chronic or progressive disease
* who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome
* who have a history of anaphylaxis, serious vaccine reactions
* who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from
* who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
* who have Down's syndrome or other known cytogenic disorders
Targeted Infection Control in Long-term Care

This is an interventional study aimed at reducing multi-drug resistance and infections in nursing home (NH) residents. Each year, a staggering 1.5-2.0 million infections occur in NHs. Many of these infections are caused by multiple drug resistant organisms (MDROs) including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multidrug resistant Gram-negative bacilli (R-GNB). Antimicrobial resistance among common bacteria are adversely affecting the clinical course and exponentially increasing healthcare costs. Recognizing a need for action, legislators, policy makers, and consumer groups are advocating for pathogen-based universal preemptive screening for these MDROs, particularly MRSA in hospitals and NHs. However, implementing this sweeping mandate is controversial, costly, reactive, and not based on empirical evidence. It can result in a 10-20-fold increase in the number of NH residents placed in isolation precautions with the potential for reduced attention by healthcare workers, isolation and functional decline. The investigators proposal evaluates a novel focused approach between 'do nothing' and 'search all and destroy' strategies by targeting a subgroup of NH residents with indwelling devices who are at a high risk of acquiring MDROs and infections.

The investigators hypothesize that the investigators targeted infection control program (TIP) will reduce MDRO colonization and infections in NH residents with indwelling devices. This cluster randomized trial will involve 12 NHs; 6 will be randomized to the TIP arm and 6 to the routine care arm. The investigators TIP intervention will include four components.

Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.

Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.

Component 3: A hand hygiene promotion program.

Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.

Eligibility Criteria:
Inclusion Criteria:

* Any short- or long-stay resident with an indwelling urinary catheter or feeding tube for more than 72 hours
* Ability to get informed consent from either the resident or his/her durable power of attorney

Exclusion Criteria:

* Having an indwelling device for less than 72 hours
* Refusal of consent to get surveillance cultures and data collection by the resident or his/her durable power of attorney
* Residents who are receiving end-of-life care
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.


Eligibility Criteria:
Inclusion Criteria:

* Have T2DM based on the disease diagnostic criteria World Health Organization (WHO) classification.
* Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to screening.
* Have a HbA1c ≥7.0% and ≤11.0%.
* Body mass index (BMI) ≤35 kilograms per meter squared.

Exclusion Criteria:

* Have used insulin therapy (outside of pregnancy) anytime in the past 1 year, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks.
* Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90 days.
* Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.
* Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.
* Have had ≥2 emergency room visits or hospitalizations due to poor glucose control.
* Have known hypersensitivity or allergy to Lantus® or its excipients.
* Are receiving chronic systemic glucocorticoid therapy at pharmacological doses or have received such therapy within 4 weeks immediately preceding screening.
* Have obvious signs or symptoms, or laboratory evidence, of liver disease.
* Have one of the following concomitant diseases: significant cardiac or gastrointestinal disease.
* Have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 milligrams per deciliter.
* Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
* Participants with active cancer or personal history of cancer within the previous 5 years.
* Are pregnant or intend to become pregnant during the course of the study.
* Are women who are breastfeeding.
Improvement of Hyperglycemia/Diabetes in Patients to Improve Safety

The goal of this project is to bring together staff and clinicians from Northwestern University/Northwestern Medical Group/Northwestern Memorial Hospital as well as patients and caregivers to assess and redesign the identification and management of hyperglycemia and diabetes during and in transitions of care. There will be 3 different groups for the study: a group of providers \[Group 1\], a group of patients/caregivers and laypersons \[Group 2\], and a stakeholder group \[Group 3\]. Participants will be asked to provide input on potential interventions for a future clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* Provider Group: Multidisciplinary clinical team (including but not limited to inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists)
* Patient, Caregiver and Layperson Group: Patients must have had hyperglycemia or diabetes at Northwestern Memorial Hospital in the last 5 years.
* Stakeholder Group: Involved in the specific care delivery of diabetes

Exclusion Criteria:

* Provider Group: None
* Patient, Caregiver, and Layperson Group: Patients will be excluded if they did not have diabetes or had hyperglycemia.
* Stakeholder Group: None
The Fontan Education Study: A Randomized Control Trial

The Fontan Education Study is a cluster randomized controlled trial evaluating the impact of a novel education program in combination with usual care, versus usual care alone, on preparing parents of children undergoing Fontan surgery for the challenges of the postoperative course.


Eligibility Criteria:
Inclusion Criteria:

* children who are planned to undergo Fontan surgery within 4-6 weeks and their parent(s)/guardian(s)

Exclusion Criteria:

* parents with \< grade 6 level of English reading.
Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD)

Premature infants with chronic lung disease (bronchopulmonary dysplasia \[BPD\]) are commonly treated with inhaled steroids, an optional treatment according to textbooks and guidelines . However, the evidence supporting this treatment in spontaneously breathing infants is limited, and based on only two randomized, placebo-controlled trials (RCT) with relative small number of infants . The Cochrane review concluded that these studies do not allow firm conclusions with regard to the efficacy of inhaled steroids in non-ventilated infants . Thus, there is no doubt that there is a need for more RCT in order to ascertain the role of inhaled steroids in infants with BPD. Because of its physical properties that theoretically make QVAR an attractive therapy in infants and studies showing it to be as effective as and with similar safety profile as other inhaled steroids in children, the investigators hypothesized that inhaled QVAR will be an effective therapy in infants with BPD.


Eligibility Criteria:
Inclusion Criteria:

1. Preterm infants with moderate to severe BPD, defined as oxygen \<30%, or \>30% or with positive pressure support at 36 weeks corrected gestational age, respectively
2. Parents signed an informed consent
3. The parents will comply with the 3 months study follow-up requirements, as judged by the site principal investigator.

Exclusion Criteria:

1. Congenital malformation
2. Cardiac disease (including active PDA)
3. Intraventricular hemorrhage grade III-IV
4. Unstable conditions such as sepsis, apneas, ets. at time of enrollment.
Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18-40 years
* Ovulatory dysfunction characterized by irregular and/or extended cycles
* Non-smoker

Exclusion Criteria:

* No previous gonadotropin treatment
* No more than 6 previous clomiphene treatment cycles